SecBot SecBot
SECBOTREPLAY Home › Report › ADCT

ADCT · Redomiciliation to Delaware

ADC Therapeutics SA · S-4 filed Nov 3, 2026 at 17:02 ET

At the news

NEUTRALIMPACT 3/10

S-4 filed Nov 3, 2026 at 17:02 ET

ADC Therapeutics SA filed a preliminary S-4 registration statement to reincorporate from Switzerland to Delaware via a redomiciliation transaction. The transaction requires shareholder approval and is expected to close by June 30, 2027, with no change in business, capitalization, or shareholder economic interest. The filing is a routine corporate restructuring with no material financial impact.

  • Board unanimously approved redomiciliation from Switzerland to Delaware under name ADC Therapeutics, Inc.
  • Each issued Swiss common share (CHF 0.08 par value) will convert 1:1 into Delaware common stock ($0.10 par value).
  • No dilution; outstanding share count unchanged post-transaction.
  • Transaction conditioned on shareholder approval, SEC effectiveness, NYSE listing, Swiss tax rulings, and creditor protections.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access